Mark A Rettenmaier

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

Radiation Therapy

Placebo Controlled

Top Venues

Journal of gynecologic oncology

The journal of obstetrics and gynaecology research

This page only lists publications with an associated author ORCID identifier.

Publications

John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration? The journal of obstetrics and gynaecology research (2023)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology (2022)